Wnt signaling in ovarian tumorigenesis

Por GATCLIFFE, T.A., MONK, B.J., PLANUTIS, K., HOLCOMBE, R.F.
Publicado em 2007

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study(†)

Por Tewari, K. S., Java, J. J., Eskander, R. N., Monk, B. J., Burger, R. A.
Publicado no Ann Oncol (2016)

HPV infection and number of lifetime sexual partners are strong predictors for ‘natural’ regression of CIN 2 and 3

Por Chan, J K, Monk, B J, Brewer, C, Keefe, K A, Osann, K, McMeekin, S, Rose, G S, Youssef, M, Wilczynski, S P, Meyskens, F L, Berman, M L
Publicado em 2003

Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Grou...

Por Phippen, N.T., Secord, A.A., Wolf, S., Samsa, G., Davidson, B., Abernethy, A.P., Cella, D., Havrilesky, L.J., Burger, R.A., Monk, B.J., Leath, C.A.
Publicado no Gynecol Oncol (2017)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-...

Por Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., Lebedinsky, C., Parekh, T., Gómez, J., Park, Y. C., Alfaro, V., Monk, B. J.
Publicado em 2011

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Por Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Vergote, I., Lebedinsky, C., Parekh, T., Santabárbara, P., Park, Y. C., Nieto, A., Poveda, A.
Publicado em 2011

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Por Chan, J.K., Brady, M.F., Penson, R.T., Huang, H., Birrer, M.J., Walker, J.L., DiSilvestro, P.A., Rubin, S.C., Martin, L.P., Davidson, S.A., Huh, W.K., O’Malley, D.M., Boente, M.P., Michael, H., Monk, B.J.
Publicado no N Engl J Med (2016)

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ov...

Por Monk, B. J., Brady, M. F., Aghajanian, C., Lankes, H. A., Rizack, T., Leach, J., Fowler, J. M., Higgins, R., Hanjani, P., Morgan, M., Edwards, R., Bradley, W., Kolevska, T., Foukas, P., Swisher, E. M., Anderson, K. S., Gottardo, R., Bryan, J. K., Newkirk, M., Manjarrez, K. L., Mannel, R. S., Hershberg, R. M., Coukos, G.
Publicado no Ann Oncol (2017)